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Abstract
Human parvovirus B19V (B19V) has been associated with various haematological disorders, but data on its prevalence in leukaemia are
scarce. In this cross-sectional study, we investigated patients in Sao Paulo, Brazil with leukaemia to determine the molecular frequency of
B19 variants and characterize the viral genetic variability by partial and complete sequencing of the coding of non-structural protein 1 (NS1)/
viral capsid proteins 1 and 2 (VP1/VP2). The presence of B19V infections was investigated by PCR ampliﬁcation of the viral NS1 gene
fragment and conﬁrmed by sequencing analysis. The NS1/VP1/VP2 and partially larger gene fragments of the NS1-positive samples were
determined by overlapping nested PCR and direct sequencing results. The B19V NS1 was detected in 40 (16%) of 249 bone marrow samples
including 12/78 (15.4%) acute lymphoblastic leukaemia, 25/155 (16.1%) acute myeloid leukaemia and 3/16 (18.7%) chronic myeloid leukaemia
samples. Of the 40 participants, 25 (62.5%) were infected with genotype 1a and 15 (37.5%) with genotype 3b. The phylogenetic analysis of
other regions revealed that 12/40 (30%) of the patients with leukaemia were co-infected with genotypes 1a and 3b. In addition, a new B19V
intergenotypic recombinant (1a/3b) and an NS1 non-recombinant genotype 1a were detected in one patient. Our ﬁndings demonstrated a
relatively high prevalence of B19V monoinfections and dual infections and provide, for the ﬁrst time, evidence of inter-genotypic
recombination in adults with leukaemia that may contribute to the genetic diversity of B19V and may also be a source of new emerging viral
strains with future implications for diagnosis, therapy and efﬁcient vaccine development.
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Introduction
The human parvovirus B19 (B19V) belongs to the genus
Erythrovirus of the family Parvoviridae and is a tiny non-
enveloped virus with linear single-stranded DNA genome. The
virus propagates in actively dividing erythroid lineage progen-
itors of bone marrow (BM) cells, inhibiting erythropoiesis [1].
The viral genome encodes three main proteins: the non-
structural protein (NS1) and two viral capsid proteins (VP1
and VP2) [2]. The minor capsid protein, VP1, has the same
amino acid sequence as VP2 plus an additional 227 amino acids
at the N-terminus: the VP1-unique region (VP1u) [3]. In
addition to NS1 and VPs, the B19V genome also encodes a 7.5-
kDa protein, an 11-kDa protein and the putative X protein.
Currently, the exact function of the 7.5-kDa protein during
B19V infection is not known but the 11-kDa protein has been
shown to regulate virion production in infected cells [4].
Although a single-stranded DNA virus, the B19V mutation
rate is higher than the rates observed in DNA viruses, and the
virus may evolve at rates similar to those of many RNA viruses
[5,6]. The current views of B19V diversity are shaped by
partially and completely sequenced viral genomes representing
three genetically distinct genotypes with more than 10% genetic
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variability among them [7–10]. These have been designated
genotype 1 (B19-related viruses), genotype 2 (A6-related
viruses), and genotype 3 (V9-related viruses). Furthermore,
recent phylogenetic analyses have revealed two subgroups
within genotypes 1 and 3 [5,11]. Most infections are caused by
genotype 1 and result in a wide range of human diseases,
including erythema infectiosum in children, arthropathy, tran-
sient aplastic crisis in patients with chronic haemolytic anaemia,
and hydrops fetalis in pregnant women [2,12]. B19V have been
increasingly proposed as responsible pathogens for acute
leukaemia because of their known erythrocyte tropism, which
makes them attractive and biologically plausible aetiological
agents [13–17]. One report suggested that the transformation
of a pre-leukaemic clone to a fully qualiﬁed malignant clone by
B19V is probably attributed to the virus-induced immune
suppression of erythroid elements in the BM, along with cell
proliferation and up-regulation of key mediators, such as
circulating granulocyte–macrophage colony-stimulating factor,
which have previously been detected at abnormally high
concentrations at the onset of acute leukaemia [14,18,19].
Another study has reported that B19V infections may impact
leukaemia by altering DNA methylation patterns and speciﬁc
key genes in susceptible cells [20,21]. Much information on the
proposed causal association of B19V infection and leukaemia
has been based on direct detection of viral genomes from the
BM of patients with leukaemia [14,21]. However, B19V DNA
has also been found in BM from healthy donors [22,23],
although the number of subjects investigated was small. These
ﬁndings leave open the question of whether B19V is the sole
culprit or merely an innocent bystander in the BM as a
consequence of an earlier infection. Generally, patients with
malignant blood conditions, particularly children with acute
lymphoblastic leukaemia (ALL), may be severely affected by the
tropism of B19 to erythroid progenitor cells.
B19V is ubiquitous worldwide. A study based on the
detection of B19V DNA in skin biopsies proposed that
genotypes 1 and 2 in northern Europe were more prevalent in
the past, but that genotype 2 was replaced by genotype 1 in the
1960s [24,25]. Conversely, B19V genotype 3 is found almost
exclusively in Ghana, although it is also found in Brazil and
France, and rarely in the USA [10,26–29]. It is possible that
genotype 3 has emerged in Africa and, after a long evolution,
has been introduced to Brazil and the USA, probably as a
consequence of the large-scale inﬂux of people of African
origin through the slave trade in the eighteenth century.
Following an acute phase, the virus may establish a
persistent infection that remains in human tissues for years
or even a lifetime [22,25,30]. In patients with ALL, infection
with B19V can cause chronic BM failure, usually manifested as
anaemia, because of its tropism for human erythroid progen-
itors [31–33]. The impacts of B19V infection during mainte-
nance chemotherapy can result in acute/chronic anaemia, pure
red cell aplasia or pancytopenia [32]. Recently, it has been
shown that patients with active B19 replication on mainte-
nance therapy had longer periods with delayed or interrupted
chemotherapy and required frequent blood transfusions [34].
Except for studies involving children with ALL, little to no
information is available on the occurrence of B19V infection
among adults with ALL or other types of leukaemia [34–38].
In the present study, we sought to determine the preva-
lence of B19V infection in all adult patients affected by
leukaemia, including ALL, acute myeloid leukaemia (AML) and
chronic myeloid leukaemia (CML), seen at our institution from
2007 to 2010. In addition, we conducted a molecular
characterization of partial and larger fragments spanning the
coding NS1/VP1/VP2 region of the isolated viruses with an aim
to providing new genetic materials that could provide infor-
mation on B19V evolution.
Materials and Methods
Patients
This study was retrospectively conducted on frozen BM
samples consecutively collected at the time of diagnosis from
155 adult patients with AML, 78 patients with ALL, and 16
patients with CML. All patients were admitted to the Sao Paulo
Clinical hospital from November 2007 to August 2010.
According to the state health department bulletin there had
been no epidemic outbreaks of erythema infectiosum in Sa˜o
Paulo during the study. At diagnosis, haematological parame-
ters were determined for all the patients through standard
methods. The diagnosis of ALL and AML was made through a
morphological evaluation of BM biopsies for which immuno-
phenotypic analysis for surface B-lymphocytic and T-lympho-
cytic markers was also performed. The CML diagnosis was
conﬁrmed by the presence of the BCR-ABL translocation by
cytogenetic analysis, ﬂuorescence in situ hybridization analysis,
or molecular analysis as previously reported [39].
The characteristics of the 249 patients herein analysed are
summarized in Table 1. Written consent was given by the
patients for their information to be stored in the hospital
database and used for research. This study was approved by
the Institutional Ethical Research Board of the Hospital das
Clı´nicas e da Faculdade de Medicina da Universidade de Sa˜o
Paulo.
Ampliﬁcation and sequencing of B19V DNA
The genomic DNA used for the PCR analyses was extracted
from BM samples with a QIAamp DNA Blood Mini Kit
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(Qiagen, Hilden, Germany), according to the manufacturer’s
instructions. To determine the prevalence of B19V infection,
all extracted DNA was initially used as a template to amplify a
424-base-pair (bp) fragment as previously described [28].
Positive and negative controls (healthy donor polymorphonu-
clear leucocytes) were included in each assay. Samples positive
for B19V were further conﬁrmed by sequencing and phyloge-
netic analysis. For ampliﬁcation and sequencing of the
complete coding NS1/VP1/VP2 region (4413 nucleotides
(nt)), we initially used the primers and protocols described
by Toan et al. [11] (hereafter referred to as strategy 1), as
these primers are able to uniquely amplify B19V genotype 1.
We also designed a set of nested speciﬁc-genotype-3 primers
to amplify two overlapping fragments that cover the entire
coding NS1/VP1/VP2 region (4432 bp, nt 515 to 4947). A
2127-kilobase (kb) fragment corresponding to the 5′-region
was ampliﬁed with the outer primers P1f and E3_n5r and the
inner primers E3_n1f and P5r (see Table 2). The 3495-kb 3′-
end fragment was ampliﬁed using the outer primers 103-OF
and 103-OR and the inner primers 101-OF1 and 104-OR. The
reaction mixtures for ﬁrst-round PCR of both fragments
contained 250–300 ng DNA template, 2 mM MgCl2, 0.1 mM
dNTPs, 0.5 lM of each primer and 2.5 U high-ﬁdelity Taq
platinum DNA polymerase (Invitrogen, Carlsbad, CA) in an
MgSO4 reaction buffer. After an initial denaturation of 5 min at
94°C, 35 cycles of 30 s at 94°C, 30 s at 55°C, 3 min at 72°C
and a ﬁnal extension at 72°°C for 5 min were performed. For
the nested PCR, 5 lL of the ﬁrst PCR was used, and the PCR
mixture and thermal proﬁle were the same as those described
above. The b-globin gene targeting the TAL57 region was used
to exclude PCR inhibitors and check for DNA integrity [40].
Each PCR included a known B19V DNA positive control and
an interspersed no DNA template negative controls. The
ampliﬁed fragments were puriﬁed using a QIAquick PCR
Puriﬁcation Kit (Qiagen, Hilden, Germany). The puriﬁed
products were directly sequenced on both strands using the
PCR inner primers and, whenever necessary, additional
internal speciﬁc primers (see Table 2) and the PRISM Big
Dye Terminator Cycle Sequencing Ready Reaction Kit
(Applied Biosystems/Perkin-Elmer, Foster City, CA) in an
automated sequencer (ABI 3130, Applied Biosystems). After
TABLE 1. Patient characteristics and ﬁndings
Characteristics
No. of samples B19V genotypes
Total B19V+ Genotype 1 Genotype 3
Total 249 40 (16%) 25 (10.04%) 15 (6.02%)
Sex
Male 139 22 (15.83%) 13 (9.35%) 9 (6.47%)
Female 110 18 (16.36%) 12 (10.91%) 6 (5.45%)
Age, years
18–29 99 (40%) 14 (15.56%) 14 (15.56%) ND
30–39 63 (25%) 13 (20.63%) 8 (12.70%) 5 (7.94%)
40–49 27 (11%) 2 (7.41%) ND 2 (7.41%)
>50 60 (24%) 11 (18.33%) 3 (5%) 8 (13.33%)
Leukaemia/lymphoma
ALL 78 (31%) 12 (15.38%) 7 (8.97%) 5 (6.41%)
AML 155 (62%) 25 (16.13%) 17 (10.97%) 2 (12.5%)
CML 16 (7%) 3 (18.75%) 8 (5.16%) 1 (6.25%)
B19V, human parvovirus B19; ND, not detected; ALL, acute lymphoid leukaemia;
AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia.
TABLE 2. Primers used for poly-
merase chain reaction ampliﬁcation
and DNA sequencing of the coding
NS1/VP1/VP2 regions of B19Vgeno-
type 3
Name Orientation Sequence 5′–3′ Positiona
E3_N1F Sense CTGCTAACTAACAGGTATTTATACTAACT 515–547
E3_N1R Antisense TAATAATGTTCTTTACCAYCTTGTAACTGA 902–873
E3_N2F Sense GAAACTTAACTGTGYGTGTAGAAGG 842–866
E3_N2R Antisense GCAGTAGTCACAGTGGCAGCT 1318–1298
E3_N3F Sense TGGTAAATTGGCTATGTGAAAACAGAG 1217–1243
E3_N4F Sense GGCCAGCCAACCAGGGTAG 1729–1747
E3_N4R Antisense GGATTGCCTGTTTGTTGTGTGGAACAT 2373–2347
E3_N5F Sense TAGGGGTTGACTTTGTATGGGATGG 2315–2339
E3_N5R Antisense TACTGGTACAGATTTAGAACTTATTCAA 2686–2659
E3_N6F Sense ACCTGTCTGGGTTACAAAGCTTTG 2540–2563
E3_N6R Antisense GCTGGGCCTCCGCAGAATGC 3003–2984
E3_N7F Sense TACACAAGCCTGGGCAAGTTAG 2913–2934
E3_N7R Antisense GCTAGTGGGAAAGAGGCGAAAGTG 3472–3449
E3_N8F Sense AGCAACCCTACAAAAAGCATGTGG 3302–3325
E3_N8R Antisense GGTGAAGTAAACACACAGGGAGTT 3841–3818
E3_N9F Sense TAGCTCCAGAACTGCCCATTTGG 3759–3781
E3_N9R Antisense GTTACAAGGGCTAAACATGCACAC 4422–4399
E3_N10F Sense CTGGGACACTGATAAATATGTAACAGG 4267–4293
E3_N10R Antisense GGCAACCATCTGTAAAGGATACAG 5028–5005
103-OF Sense TAGTACTTTTTTGTTACATTCAGACTTTGAG 1431–1461
104-OR Antisense GGATATGAAAAGCCTGAAGAATTGTGGACT 4942–4913
103-OF Antisense GCCTGAAGAATTGTGGACTGCCAA 4947–4924
103-OF Sense TAGTACTTTTTTGTTACATTCAGACTTTGAG 1431–1461
104-OR Antisense GGATATGAAAAGCCTGAAGAATTGTGGACT 4942–4913
103-OF Antisense GCCTGAAGAATTGTGGACTGCCAA 4947–4924
P1fb Sense TGTGAGCTAACTAACAGGTATT 570–591
P5rb Antisense ATTCCACAAATTGCTGATACAC 2677–2699
aNucleotide numbering according to position based on the sequence of B19 isolate J35 (GenBank accession no.
AY386330).
bToan et al., 2006 [11].
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excluding the primer regions, the fragments for each amplicon
were assembled into contiguous sequences and edited with
SEQUENCHER 4.7 (Gene Code Corp., Ann Arbor, MI) using the
default parameters.
Phylogenetic tree analyses and genotype determination
The B19V genotypes were determined by phylogenetic tree
analysis, including all the B19V complete genomes of prototype
strains (as of October 2011) from GenBank. Viral sequences
were aligned using the CLUSTAL X program [41] Software
alignment was followed by manual editing in the BIOEDIT
SEQUENCE ALIGNMENT EDITOR program [42] to maximize similar-
ity while maintaining consistency in the reading frames. The
genetic distances were calculated by the maximum composite
likelihood method, and phylogenetic trees were constructed
using the neighbour-joining [43] method as implemented in
MEGA version 5.0 software. The reliabilities of the branches
were evaluated by bootstrap analysis with 1000 re-samplings.
The sequences from which either partial or complete coding
genomic regions were strongly positioned inside one of the
genotype reference groups were compiled and their respective
genotypes were assigned. The sequences suggestive of recom-
bination by the above phylogenetic inferences that presented
unclear clustering were subjected to recombination analysis.
For this analysis, the bootscanning method [44] implemented
in SIMPLOT v. 3.5.1 for Windows [43] was used with the
following parameters: window size 250 bp, step size 20 bp,
F84 model of evolution (maximum likelihood) as the model to
estimate nucleotide substitution, transition/transversion ratio
of 2.0, and a bootstrap of 100 trees. The signiﬁcance threshold
for the bootscan was set at 70%. The positions of crossover
sites were deﬁned based on the distribution of informative
sites supporting the two incongruent topologies that maxi-
mized the chi-square value [45], a method implemented in
SIMPLOT. Trees were displayed using MEGA version 5.0 software.
Statistical analysis
Differences between data groups were analysed with the
Fisher’s exact test or chi-square test with Yate’s correction
when appropriate. The two-tailed Mann–Whitney U test was
employed for comparison of age differences between the
groups as stratiﬁed by infecting B19V genotype. A p value
<0.05 was considered signiﬁcant. The data were analysed with
STATA statistical software (StataCorp, release 5.0, 1997; Stata
Corp., College Station, TX).
FIG. 1. Neighbour-joining inferred rooted phylogeny of a partial
human B19V non-structural protein 1(NS1) sequence. The black circle
denotes variants detected in patients surveyed in this study. The star
symbol indicates patients dual-infected with genotypes 1a and 3b, as
later determined by strategies 1 and 2. Bootstrap replication frequen-
cies  70% are indicated above nodes. Genotypes and subgenotypes
are indicated at the corresponding nodes. The tree was rooted on
Rhesus macaque parvovirus (GenBank AF221122). Branch lengths are
drawn to scale.
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GenBank accession numbers
All nucleotide sequences were reported to the GenBank
database (GenBank accession no. KC013302-KC013351).
Results
Ampliﬁcation of the partial B19V NS1 genome was observed in
40 of 249 BM samples (16%) from patients with a conﬁrmed
diagnosis of leukaemia. Of these patients, B19V positivity was
detected in 12 of 78 (15.4%) ALL patients, 25 of 155 (16.3%)
AML patients, and 3 of 16 (18.7%) CML patients. No
statistically signiﬁcant differences were observed among the
considered groups. Partial sequences of the NS1 gene were
successfully obtained from all B19V-positive samples. Phyloge-
netic analysis of these sequences, together with 43 corre-
sponding region sequences of selected B19V strains available in
GenBank, revealed the presence of genotype 1a (62.5%) and
genotype 3b (37.5%) viruses (Fig. 1). No sample was positive
for the B19V genotype 2. Among the 78 ALL samples, seven
isolates clustered with genotype 1a and ﬁve clustered with
genotype 3b prototype strain sequences. Among the 155 AML
specimens, 17 isolates were characterized as genotype 1a and
eight as genotype 3b viruses. In 16 CML patients, one sample
was characterized as genotype 1a and two as genotype 3b
viruses. A pattern of sequence segregation was supported by
>80% bootstrap values in all analyses, as indicated at the
respective branches (Fig. 1). Among the partial NS1 genomic
regions examined, the isolates closely related to the reference
genotype 1 sequences had inter-strain genetic distances (d) of
8%, with a range of 0.3–16.7%. Within genotype 1a, the viral
sequences were more closely related to each other
(d = 0.9%); diversity between isolates ranged only from 0.3%
to 2.4%. In contrast, the isolates closely related to the
reference genotype 3 sequences had an inter-strain d of 8.2%,
with a range of 0.3–17.5%. Within genotype 3b, virus
sequences were less distantly related to each other (d =
FIG. 2. Neighbour-joining inferred rooted phylogeny of human B19V
non-structural protein 1/viral capsid proteins 1 and 2 (NS1/VP1/VP2)
sequence. The black circle denotes variants detected in patients with
partial human B19V NS1 sequences. The star symbol indicates patients
dually infected with genotype 3b, as later conﬁrmed by strategy 2. The
black triangle symbol indicates an isolate forming a unique branch in
genotype 1 separate from 1a and 1b, which appeared in further analysis
as a 1a/3b recombinant (see Fig. 3). Bootstrap replication frequencies
 70% are indicated above nodes. Genotypes and subgenotypes are
indicated at the corresponding nodes. The tree was rooted on Rhesus
macaque parvovirus (GenBank AF221122). Branch lengths are drawn
to scale.
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2.3%); diversity between isolates ranged only from 0.3% to
4.7%. The phylogenetic analysis of B19V sequences obtained in
this study indicated that they did not form a single monophy-
letic cluster but instead belonged to genotype 1a and 3b in
various subclusters, most of which had no signiﬁcant bootstrap
support.
To conﬁrm the consistency of the genotyping, allow a more
advanced phylogenetic analysis and provide a set of reference
sequences for each viral genotype, the 40 samples with NS1
sequences were subjected to ampliﬁcation and sequencing of
the complete coding NS1/VP1/VP2 regions of B19V using
strategy 1. Of these, 20 sequences were obtained for all ten
overlapping fragments that covered the complete coding
regions of the 40 patients. Partial sequences were obtained
from at least one fragment derived from 16 samples as shown
in Table 3. In the phylogenetic tree of the partial sequences
shaded in Table 3, isolate 07BRSP7612 forms a unique branch
in genotype 1, suggesting a new subgroup (Fig. 2). However,
further analysis using SIMPLOT and bootscanning of the ampliﬁed
fragment indicated a single recombinant event between
genotype 1a (between nt 949 to 1879) and genotype 3b
(between nt 1886 to 2160) (Fig. 3a). To further conﬁrm this
result, phylogenetic trees were generated for the nucleotide
sequence regions on either side of the breakpoint. This
analysis corroborated the results from the bootscan and so
provides unambiguous evidence for recombination events
supported by high bootstrap values (Fig. 3b). Crucially, the
breakpoint was detected in a position far from the regions
containing sequences identical or complementary to the
sequences of oligonucleotide primers used for PCR or
sequencing, demonstrating that this breakpoint is indeed a
bona ﬁde recombinant rather than a laboratory artefact. Next,
we aimed to investigate the phylogenetic correlation of the
genotype 3b fragment involved in the recombinant event as
deﬁned by bootscan and the non-recombinant genotype 3b
fragment from the same patient as deﬁned by strategy 2
(Table 4). The result of the neighbour-joining tree depicted in
Fig. 4 revealed both sequences clustered on a genotype 3
branch and further into one separate sub-branch supported by
a high bootstrap value (86%). Moreover, the alignment of the
(a) (b)
(a) (b)
(a) (b)
FIG. 3. Exploratory tree analysis based on fragments between breakpoints as indicated by a bootscan plot of isolate 07BRSP7612. The neighbour-
joining tree was established from the alignments of the non-structural protein 1 (NS1) fragment spanning nucleotide positions 949–1874 (a) and
positions 1886–2160 (B19 isolate J35 GenBank accession no. AY386330) (b) for isolate 07BRSP7612 (indicated by black circle) and other B19V
reference genotypes. Bootstrap replication frequencies  70% are indicated above nodes. Genotypes and subgenotypes are indicated at the
corresponding nodes. The tree was rooted on Rhesus macaque parvovirus (GenBank AF221122). Branch lengths are drawn to scale.
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sequenced fragments did slightly differ from each other in the
manner expected for related genotype 3 viruses that have
diverged through independent evolution. Based on this ﬁnding,
it is possible that the recombination event that produced the
1a/3b isolate took place in patient 07BRSP7612, who was
found to also be co-infected with non-recombinant genotype
3b strains. In contrast to recombination analysis, visual
inspection of a tree constructed from the samples with
complete coding NS1/VP1/VP2 regions (Tables 3 and 4)
revealed that sequence 07BRSP7612 grouping with B19V
genotype 1a with high statistical support (data not shown).
This observation was not surprising, given the short sequence
of the putative recombinant region (Fig. 5).
Surprisingly, when analysed with other B19V reference
sequences, all strains obtained by strategy 1 clustered signif-
icantly with B19V genotype 1a (Fig. 2). The conﬂicting
phylogenetic data, such as the data obtained for the partial
NS1 and the complete coding NS1/VP1/VP2 sequences in
samples marked with a star symbol in Tables 3 and 4 and
Fig. 2, were indicative of the presence of a mixed infection of
subgenotype 1a and and subgenotype 3b. These results also
raised doubts about the speciﬁcity of the primers used in
strategy 1 to amplify genotype 2 and 3. As a consequence, the
BLAST search of each primer indicated high bias in favour of
genotype 1 and 2 ampliﬁcation. These ﬁndings prompted us to
search for an alternative approach to enable construction of a
phylogenetic tree of B19V genotype 3 from longer fragments
(hereafter referred to as strategy 2). For that purpose, we
used strategy 2 to amplify and sequence the 40 samples
positive for NS1 sequences as mentioned in the Materials and
Methods. The strategy 2 ampliﬁcation results are summarized
in Table 4. With the exception of sample 07BRSP7612,
subsequent phylogenetic analysis of the ampliﬁed products
indicated identical genotyping 3b results to those obtained by
analysis of the partial NS1 fragment. The phylogenetic analysis
of the sequences obtained by strategies 1 and 2 from sample
07BRSP7612 indicated that this patient had been doubly
infected with genotype 1a/3b recombinant and genotype 3
viruses. In all partial and long-fragment analyses, no identical
virus sequences were found among the 40 B19V-infected
patients, conﬁrming the absence of PCR contamination.
Indeed, we could not see any signal of mixed bases on the
initial analysis of the NS1 partial sequences from the dually
infected samples (as deﬁned later by the genotype-speciﬁc
primers used for strategies 1 and 2). Although quantiﬁcation of
viral load was not performed in our subjects, it is possible that
mixtures of different genotypes were present in the same
sample and the identiﬁcation of both genotypes may be
compromised if one of the other viral variants is present at a
lower load.T
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The detection of both viruses in a single clinical sample
strongly suggests that the presence of the two variants was the
result of either co-infection or superinfection. However, only
the frequency of dual infection was noted in this study because
we do not know whether co-infection or superinfection
originally occurred.
In our samples, subjects infected with non-recombinant
genotype 3b viruses were older than patients infected with
genotype 1 viruses. However, the differences between the two
groups did not reach statistical signiﬁcance because sample
sizes were very small for the patients only infected with
genotype 3b (n = 4; mean age, 31.6 years versus 46.7 years,
respectively; p 0.051, Mann–Whitney U test). For this reason,
patients mono-infected with genotype 3 and patients
co-infected with genotypes 1a, 3b and 1a/3b recombinant
were grouped together and compared with patients infected
with non-recombinant genotype 1 in subsequent analyses. This
analysis revealed a marked difference between the groups
(mean age, 62.5 years versus 47.2 years, respectively; p <0.01,
Mann–Whitney U test) (Table 5).
Discussion
In this study, we aimed to investigate the putative occurrence
of B19V in adults with different types of leukaemia. The 16%
prevalence of B19V positivity in this group of patients is in the
range of 5.7–68.8% in children and adults with haematological
disorders, including leukaemia, that has been reported by our
group and others [17,21,23,28,34,46,47]. The divergence in
prevalence rates may reﬂect geographic differences in the
spread of the virus in diverse parts of the world, methodo-
logical differences in diagnostic procedures, differences in
sample size, or differences in the degree of immunosuppres-
sion associated with the duration and dose intensities of
patient chemotherapies. Using phylogenetic analysis, we dem-
onstrated that at least two B19V genotypes, 1a and 3b, are
currently present in patients with leukaemia. In agreement
with previous studies, our results indicated signiﬁcantly well-
deﬁned subgenotypes within genotypes 1 and 3 [5,48,49].
Moreover, we did not ﬁnd any sample positive for genotype 2.
FIG. 4. Neighbour-joining inferred rooted
phylogeny of the genotype 3b fragment involved
in the recombinant event as deﬁned by boot-
scan (274 base pairs, nucleotides 1886–2160 of
B19 isolate J35 GenBank accession no.
AY386330) and the non-recombinant genotype
3b fragment as deﬁned by strategy 3 from the
07BRSP7612 isolate (indicated by black circle).
Bootstrap replication frequencies  65% are
indicated above nodes. Genotypes and subge-
notypes are indicated at the corresponding
nodes. The tree was rooted on simian parvo-
virus (GenBank accession no AF221122).
Branch lengths are drawn to scale.
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As the partial NS1 PCR assay used was equally sensitive to
B19V variant genomes, the lack of genotype 2 most likely
indicates a real absence of this genotype from the subjects
examined in the present study. Alternatively, it is possible that
we may have failed to amplify genotype 2 in some patients if
they had B19V levels below the detection limit of our assay.
The detection of genotypes 1 and 3 in Brazilian patient
samples was expected. The majority of B19V Brazilian isolates
described have been afﬁliated with these genotypes
[23,28,48,49]. The results of phylogenetic analysis indicated
that genotype 3b sequences from Brazil did not group as a
speciﬁc, closely related cluster as was observed with the
isolates from genotype 1a. Moreover, the genotype 1a isolates
were more closely related to each other than the genotype 3b
isolates. These observations may suggest that B19V genotype
3b has been present in Brazil for a very long time and that
genotype 1a isolates were introduced relatively recently.
Although speculative at this point, this observation should be
amenable to robust phylogenetic testing analysis like a Bayesian
coalescent approach on more sequences with time informa-
tion to understand the origin and evolution of B19V genotypes
in Brazil.
Our results also demonstrated that patients infected only
with non-recombinant genotype 1a were on average younger
than patients who were mono-infected or co-infected with
genotype 3b. These results are in accordancewith data collected
from central and northern Europe, suggesting that the circula-
tion of genotype 2 viruses ceased in the late 1960s and that
genotype 1 is now the most prevalent in those areas [24,25].
The fact that the majority of patients infected with genotype 1a
were younger on average suggests that different B19V geno-
types do not induce distinct immunological responses.
(a) (b) (c)
FIG. 5. Exploratory tree analysis based on fragments between breakpoints as indicated by a bootscan plot of isolate 07BRSP7612 complete coding
non-structural protein 1/viral capsid proteins 1 and 2 (NS1/VP1/VP2) sequence. The neighbour-joining tree was established from the alignments
spanning nucleotide positions 913–1925 (a), 1929–2127 (b), and positions 2144–5023 (c) (B19 isolate J35 GenBank accession no. AY386330). Isolate
07BRSP7612 is indicated by circle. Bootstrap replication frequencies  70% are indicated above nodes. Genotypes are indicated at the corresponding
nodes. Branch lengths are drawn to scale.
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The observation that patients may be simultaneously
infected with different B19V genotypes is of considerable
interest. Schneider et al. [50] found that 4 of 59 study
participants presented the simultaneous persistence of two
genotypes. In another study, Corcioli et al. [51] noted mixed
infections by genotype 1 and 2 in one bioptic sample and also
observed DNA of both genotypes in two other patients who
had genotype 1 in their serum samples and genotype 2 in their
tissue samples. In the present study, there was a relatively high
rate of dual infections involving genotypes 1a and 3b,
suggesting that this event is far more common in Brazil where
both genotypes co-circulate. Furthermore, it is likely that B19V
co-infection/superinfection occurred repeatedly in patients
with leukaemia, given that 12% of our subjects were co-
infected with genotypes 1a and 3b. The fact that our patients
had a relatively high rate of dual infection goes against the
hypothesis that an initial B19V infection produces some degree
of protection against second infecting genotypes. If we assume
that superinfection occurs, then it is conceivable that these
patients may have been less able to prevent infection with a
second strain than they would have been if they had had
sufﬁciently broad protection at the time of primary infection,
as has been speculated by Schneider et al. [50]. The impact of
repeated exposure to B19V may be the weakening or
exhaustion of the virus-speciﬁc immune response, making an
individual more likely to be re-infected. Another possibility is
that these patients were re-infected before their primary
adaptive response had sufﬁciently matured. Alternatively, the
subjects may have been concomitantly infected with two
genotypes at the same time, but this is less likely. It is evident
that new research with longitudinally collected samples is
needed to investigate the cellular immune responses against
the primary viral variant and a subsequent re-infection variant
to support or refute the hypothesis of cross-genotype
immunity and protection against B19V persistent infection.
On the other hand, frequent detection of coexisting B19V
distinct genotypes might invariably lead to recombination [6,
52]. The latter was indeed observed in one sample infected
with genotype 1a/3b recombinant and genotype 3 viruses. To
our knowledge, the present report is the ﬁrst to describe the
occurrence of inter-genotype B19V recombinant in a single
host. It is possible that recombination of intra- and inter-B19V
genotypes occurs in countries where different viral genotypes
co-circulate, but the current techniques for assigning consen-
sus sequences will greatly hinder their detection except in
cases where the genotypes represent the dominant viral
population or more studies based on conventional clonal or
high-throughput sequencing are undertaken.
Possible intergenotypic recombination mechanisms remain
unclear. One possibility is that the positive and negative
strands of different B19V single-stranded variants anneal during
replication, as has been described with adeno-associated virus
recombinants [53]. The fact that we do not yet know whether
recombination poses a real threat justiﬁes a more thorough
investigation into the nature of this phenomenon in B19V
viruses.
Our study has several limitations, particularly its retrospec-
tive design, lack of a control group and the absence of data
regarding the clinical symptoms associated with B19V infec-
tion. In addition, the lack of a quantiﬁed B19V viral load and
serological work-up limit the diagnostic accuracy of our
analysis to qualitative B19V DNA PCR. As the mere presence
of B19V in BM does not predict a pathogenic role, the best
technical method to prove a pathogenic role for B19V may
involve quantitative PCR, serological testing, or both. In spite
of these caveats, our data add to the knowledge of the
prevalence of B19V single or mixed infections caused by
genotype 1 and 3 viruses in patients with different type of
TABLE 5. Summary of B19V-infected patients surveyed
Sample ID Ageb Gender Leukaemia B19V genotype
07BRSP7044 35 F AML 1a (C)
07BRSP7611 30 M AML 1a (C)
07BRSP7612c 22 M AML 1a (C)/3b (P)
08BRSP1565 68 M AML 1a (P)
08BRSP1591 73 M AML 1a (P)
08BRSP1662 58 F AML 1a (P)
08BRSP3007a 60 F AML 1a (C)/3b (P)
08BRSP4111 32 M ALL 1a (C)
08BRSP8255a 76 M AML 1a (P)/3b (C)
08BRSP9405 26 F AML 1a (C)
09BRSP0491 25 F AML 1a (C)
09BRSP0502 18 M AML 1a (C)
09BRSP0883 18 M AML 1a (C)
09BRSP1067 36 M CML 1a (C)
09BRSP2002 18 F ALL 1a (C)
09BRSP2051 34 F AML 1a (C)
09BRSP2079a 60 M AML 1a (P)/3b (C)
09BRSP2330 54 F ALL 3b (C)
09BRSP2361a 36 F ALL 1a (P)/3b (P)
09BRSP2910a 45 M AML 1a (P)/3b (P)
09BRSP3933 23 M ALL 1a (C)
09BRSP5027 30 F ALL 3b (P)
09BRSP5100 61 F AML 3b (P)
09BRSP6081 33 F ALL 1a (C)
09BRSP6547 28 M AML 1a (C)
09BRSP6896 28 M AML 1a (C)
09BRSP7291 23 M ALL 1a (C)
09BRSP7474a 38 M AML 1a (P)/3b (C)
09BRSP9563 42 M CML 3b (C)
10BRSP0109 37 F AML 1a (C)
10BRSP0150 20 F ALL 1a (C)
10BRSP0192a 53 M ALL 1a (P)/3b (C)
10BRSP0389a 59 F ALL 1a (P)/3b (C)
10BRSP1090 18 F AML 1a (C)
10BRSP1966a 33 M AML 1a (C)/3b (C)
10BRSP2014 18 F AML 1a (C)
10BRSP2058a 39 M CML 1a (P)/3b (P)
10BRSP2161a 66 M AML 1a (P)/3b (C)
10BRSP2230 22 F AML 1a (C)
10BRSP2440 38 M ALL 1a (C)
F, female; M, male; P, partial genome; C, complete coding NS1/VP1/VP2 region
(non-structural protein 1/viral capsid proteins 1 and 2); B19V, human parvovirus
B19; ND, not detected; ALL, acute lymphoid leukaemia; AML, acute myeloid
leukaemia; CML, chronic myeloid leukaemia.
aEvidence of genotype 1a and 3b dual infection;
bDifference in age between infection involving genotypes 3, and genotype 1,
p <0.01 (Mann–Whitney U test).
cEvidence of recombination event.
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leukaemia and provide information from a country where such
a phenomenon is rarely documented.
Overall, the data presented demonstrates a relatively high
prevalence of B19V mono-infection and co-infection in patients
with leukaemia and provides, for the ﬁrst time, evidence of
intergenotype recombination in a single patient. Such recom-
bination may contribute to the genetic diversity of B19V and
may also be a source of emergence for new viral strains.
Detection of B19V DNA in patients with leukaemia as
described in the present study does not prove causality. The
virus might merely be an innocent passenger that was detected
by chance or might become clinically relevant in this popula-
tion as a result of treatment, as patients may become
vulnerable to reactivation of persistent virus or re-infection
following BM transplantation and the introduction of immu-
nosuppressants. Therefore, further investigation of a large
population of leukaemia patients using well-matched control
groups and sequential samples will be required to elucidate the
possible pathogenic impact of B19V infections.
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